English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

tardive dyskinesia/seizures

The link is saved to the clipboard
Page 1 from 50 results

Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial.

Only registered users can translate articles
Log In/Sign up
Once developed, tardive dyskinesia (TD) is a challenging condition to treat. The recent evidence has indicated that zonisamide, an antiepileptic drug indicated for partial-onset seizures, may also have beneficial effects for ameliorating dyskinesia in Parkinson's disease. However, this finding has

Haloperidol-induced tardive dyskinesia in monkeys.

Only registered users can translate articles
Log In/Sign up
In three cebus monkeys the chronic daily administration of haloperidol (0.5 mg/kg/day orally) created sedation and parkinsonism during the first 5-7 weeks. Later the animals developed signs reminiscent of acute dystonia, as seen in the clinic during treatment with neuroleptics. These signs were

Tardive dyskinesia in northern Israel: preliminary study.

Only registered users can translate articles
Log In/Sign up
Tardive dyskinesia (TD) is an iatrogenic syndrome caused by long-term treatment with neuroleptics and is characterized by abnormal involuntary movements in the orofacial region, lingual dyskinesia and in some cases dyskinesia also in the extremities, head and trunk. In the present study we found 20%

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Only registered users can translate articles
Log In/Sign up
BACKGROUND Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD. OBJECTIVE To determine the effects

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Only registered users can translate articles
Log In/Sign up
BACKGROUND Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD. OBJECTIVE To determine the

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Only registered users can translate articles
Log In/Sign up
BACKGROUND Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. The gamma-aminobutyric acid (GABA) agonist drugs have been trialed as a treatment for TD, but these drugs have intense sedative properties and may exacerbate psychotic

Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.

Only registered users can translate articles
Log In/Sign up
Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD. 1. Primary objectiveThe primary objective was

Clozapine in tardive dyskinesia.

Only registered users can translate articles
Log In/Sign up
Clozapine, which has had limited clinical testing in the U.S.A., was evaluated in 12 chronic schizophrenic patients with tardive dyskinesia. Its antipsychotic activity was again demonstrated and it suppressed the symptoms of tardive dyskinesia with a marked rebound occurring in these symptoms when

Neurologic complications of drugs. Tardive dyskinesias, neuroleptic malignant syndrome, and cocaine-related syndromes.

Only registered users can translate articles
Log In/Sign up
Drugs, either self-administered or prescribed by physicians, can result in substantial neurologic disability in psychiatric patients. It is clear that the use of neuroleptic agents to treat psychiatric illness may result in a variety of tardive movement disorders. Most commonly, these take the form

Drug-induced taste disorders.

Only registered users can translate articles
Log In/Sign up
Numerous drugs have the potential to adversely influence a patient's sense of taste, either by decreasing function or producing perceptual distortions or phantom tastes. In some cases, such adverse effects are long lasting and cannot be quickly reversed by drug cessation. In a number of cases,

Clozapine therapy in patients with neurologic illness.

Only registered users can translate articles
Log In/Sign up
OBJECTIVE This review will analyze the use of clozapine in patients with neurologic illness. METHODS A review of the literature was performed. Attention is focused particularly on patients with seizure disorder, head injury, mental retardation, Parkinson's disease, Huntington's disease, tardive

A review of clinical trials of lithium in neurology.

Only registered users can translate articles
Log In/Sign up
Lithium has been put to clinical trials in no less than fifteen neurological disorders. They are Huntington's chorea, tardive dyskinesia, spasmodic torticollis, Tourette's syndrome, L-dopa induced hyperkinesia and the "on-off" phenomenon in parkinsonism, organic brain disorders secondary to

Deep brain stimulation: current status.

Only registered users can translate articles
Log In/Sign up
In the last two decades, applications of deep brain stimulation (DBS) have expanded rapidly in the field of neurosciences. The most common indications for DBS are Parkinson's disease, medically refractory seizures, essential tremors, and primary dystonia. This device has also been used as an

Clozapine safety, 40 years later.

Only registered users can translate articles
Log In/Sign up
Clozapine is, and will remain in the coming years, an irreplaceable drug in psychiatry which has elective indication in treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease,

Burns in the disabled.

Only registered users can translate articles
Log In/Sign up
A retrospective analysis of 812 patients admitted to the Ross Tilley Burn Centre between 1984 and 1992 resulted in 37 cases of burn injuries which were directly related to premorbid disabilities. The majority of these burns (83.8 per cent) occurred in the patient's home, most commonly as scald
Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge